Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Capital Leases (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Capital Leases readings, the most recent being $1000.0 for Q1 2026.

  • Quarterly Capital Leases fell 90.0% to $1000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1000.0 through Mar 2026, down 90.0% year-over-year, with the annual reading at $4000.0 for FY2025, 66.67% down from the prior year.
  • Capital Leases hit $1000.0 in Q1 2026 for DiaMedica Therapeutics, down from $4000.0 in the prior quarter.
  • Across five years, Capital Leases topped out at $377000.0 in Q1 2023 and bottomed at $1000.0 in Q4 2023.
  • Average Capital Leases over 5 years is $52187.5, with a median of $7500.0 recorded in 2022.
  • The largest annual shift saw Capital Leases skyrocketed 5000.0% in 2023 before it tumbled 95.52% in 2024.
  • DiaMedica Therapeutics' Capital Leases stood at $4000.0 in 2022, then tumbled by 75.0% to $1000.0 in 2023, then skyrocketed by 1100.0% to $12000.0 in 2024, then tumbled by 66.67% to $4000.0 in 2025, then tumbled by 75.0% to $1000.0 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Capital Leases are $1000.0 (Q1 2026), $4000.0 (Q4 2025), and $7000.0 (Q3 2025).